Iron supplementation for reducing morbidity and mortality in children with HIV

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Adetifa, Ifedayo M O ^a   Okomo, U ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

CHILDHOOD DISEASE; DATA BASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON THERAPY; METHODOLOGY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; REVIEW; TREATMENT RESPONSE;

EID: 44949176570     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006736     Document Type: Review

References (28)

1. Adetifa 2006 Adetifa IMO, Temiye EO, Akinsulie AO, Ezeaka VC, Iroha EO. Haematolgical abnormalities associated with paediatric HIV/AIDS in Lagos. Ann Trop Paediatr 2006;26:121-125.
2. Adewuyi 1994 Adewuyi J, Chitsike I. Haematologic features of the human immunodeficiency virus (HIV) infection in black children in Harare. Cent Afr J Med 1994;40:333-336.
3. Allen 1998 Allen UD, King SM, Gomez MP, et al.Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children. AIDS 1998;12:1785-1791.
4. Boelaert 1996 Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection:mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5:36-46.
5. Butler 1991 Butler KM, Husson RN, Balis FM, et al.Dideoxyinosine in children with symptomatic HIV infection. N Engl JMed 1991;324:137-144.
6. Carr 1998 Carr JM, Ramshaw HS, Li P, Burrell CJ. CD34+ cells and their derivatives contain mRNA for CD4 and HIV co-receptors and are susceptible to infection with M- and T-topic HIV. J Gen Virol 1998;79:71-75.
7. CDC 1994 Centres for Disease Control and Prevention. 1994 revised classification for human immunodeficiency virus infection in children less than 13 years of age. Morb Mort Wkly Rev 1994;43(RR-12):1-10.
8. Clark 2002 Clark TD, Mmiro F, Ndugwa C, et al.Risk factors and cummulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. Ann Trop Paediatr 2002;22:11-17.
9. Costagliola 1994 Costagliola DG, Montalembert M, Lefrere JJ. Dose of deferroxamine and evolution of HIV-1 infection in thalassaemic patients. Brit J Hematol 1994;87:849-852.
10. Coyle 1997 Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin N Am 1997;81:449-470.
11. De Monye 1999 De Monye C, Karcher DS, Boelaert JR, Gordeux VR. Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS 1999;13:375-380.
12. Delanghe 1998 Delanghe JR, Langlois MR, Boelaert JR. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS 1998;12:1027-1032.
13. Eley 2002 Eley BS, Sive AA, Shuttleworth M, Hussey GD. A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town, South Africa. BMC Infectious Diseases 2002;2(3).
14. Ellaurie 1990 Ellaurie M, Burn ER, Rubinstein A. Haematologic manifestations in paediatric HIV infection:severe anaemia as a prognostic factor. Am J Pediatr Hematol Oncol 1990;12:449-453.
15. Feelders 1999 Feelders RA, Kuiper EPA-Kramer, van Eijk HG. Structure, function and clinical significance of transferrin receptors. Clin Chem Lab Med 1999;37:1-10.
16. Forsyth 1996 Forsyth BN, Andiman WA, O'Connor T. Development of a prognosis based clinical staging system for infants infected with human immunodefiency virus. J Pediatr 1996;129:648-655.
17. Moore 1999 Moore RD. Human immunodeficiency virus infection, anaemia and survival. Clin Infect Dis 1999;29:44-9.
18. Olsen 2004 Olsen A, Mwanniki D, Krarup H, Friis H. Low-dose iron supplementation does not increase HIV-1 load. J Acquir Immune Defic Syndr 2004;36:637-638.
19. Pizzo 1988 Pizzo PA, Eddy J, Falloon J, et al.Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-896.
20. Richman 1987 Richman D, AZT Collaborative Working Group. The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192.
21. Salmon-Ceron 1995 Salmon-Ceron D, Fontbonne A, Saba J. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-664.
22. Savarino 1999 Savarino A, Pescarmona GP, Boelaert JR. Iron metabolism and HIV infection:reciprocal interactions with potentially harmful consequences?. Cell Biochem Funct 1999;17:279-287.
23. Semba 2001 Semba RD, Gray GE. The pathogenesis of anaemia during human immunodeficiency virus infection. J Invest Med 2001;49:225- 239.
24. Totin 2002 Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, Semba RD. Iron deficiency anaemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. J Nutr 2002;132:423-9.
25. Volberding 2000 Volberding P. Consensus statement:anaemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther 2000;22:1004-1020.
26. WHO 2001 UNICEF/WHO/UNU. Iron Deficiency Anaemic-Assessment, Prevention, and Control. A guide for programme Managers. http//:www.who.int/ nutrition/publications/en/ida_assessment_prevention_control.pdf. 2001.
27. WHO 2006 World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource limited settings:towards universal access. Recommendations for a public health approach. Geneva: 2006.
28. Zauli 1994 Zauli G, Furlini G, Vitale M. A subset of human CD34+ haematopoietic progenitors express low levels of CD4, the high affinity receptor for human immunodeficiency virus-type 1. Blood 1994;84:1896-1905.